Format

Send to

Choose Destination
Blood. 2017 Jun 29;129(26):3419-3427. doi: 10.1182/blood-2017-02-765685. Epub 2017 Apr 19.

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Author information

1
Division of Hematology and.
2
Department of Health Science Research, Mayo Clinic, Rochester, MN.
3
Department of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ.
4
Division of Hematopathology.
5
Department of Radiology.
6
Department of Laboratory Medicine and Pathology, and.
7
Department of Immunology, Mayo Clinic, Rochester, MN; and.
8
Division of Hematology, Mayo Clinic, Jacksonville, FL.

Abstract

Chronic lymphocytic leukemia (CLL) patients progressed early on ibrutinib often develop Richter transformation (RT) with a short survival of about 4 months. Preclinical studies suggest that programmed death 1 (PD-1) pathway is critical to inhibit immune surveillance in CLL. This phase 2 study was designed to test the efficacy and safety of pembrolizumab, a humanized PD-1-blocking antibody, at a dose of 200 mg every 3 weeks in relapsed and transformed CLL. Twenty-five patients including 16 relapsed CLL and 9 RT (all proven diffuse large cell lymphoma) patients were enrolled, and 60% received prior ibrutinib. Objective responses were observed in 4 out of 9 RT patients (44%) and in 0 out of 16 CLL patients (0%). All responses were observed in RT patients who had progression after prior therapy with ibrutinib. After a median follow-up time of 11 months, the median overall survival in the RT cohort was 10.7 months, but was not reached in RT patients who progressed after prior ibrutinib. Treatment-related grade 3 or above adverse events were reported in 15 (60%) patients and were manageable. Analyses of pretreatment tumor specimens from available patients revealed increased expression of PD-ligand 1 (PD-L1) and a trend of increased expression in PD-1 in the tumor microenvironment in patients who had confirmed responses. Overall, pembrolizumab exhibited selective efficacy in CLL patients with RT. The results of this study are the first to demonstrate the benefit of PD-1 blockade in CLL patients with RT, and could change the landscape of therapy for RT patients if further validated. This trial was registered at www.clinicaltrials.gov as #NCT02332980.

PMID:
28424162
PMCID:
PMC5492091
DOI:
10.1182/blood-2017-02-765685
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center